Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia
Cardiac iron overload causes most deaths in beta-thalassemia major. The efficacy of deferasirox in reducing or preventing cardiac iron overload was assessed in 192 patients with beta-thalassemia in a 1-year prospective, multicenter study. The cardiac iron reduction arm (n = 114) included patients wi...
Main Authors: | Pennell, D.J., Porter, J.B., Cappellini, M.D., El-Beshlawy, A., Chan, L.L., Aydinok, Y., Elalfy, M.S., Sutcharitchan, P., Li, C.K., Ibrahim, H., Viprakasit, V., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B., Taher, A. |
---|---|
Format: | Article |
Published: |
2010
|
Subjects: |
Similar Items
-
Continued improvement and normalization of myocardial T2*in patients with beta-thalassemia major treated with deferasirox (Exjade (R)) for up to 3 years
by: Pennell, D., et al.
Published: (2010) -
Deferasirox effectively removes cardiac iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone therapy
by: Pennell, D., et al.
Published: (2010) -
Continued improvement in cardiac T2*with deferasirox treatment over 2 years: Results from the extension of epic cardiac substudy in beta-thalassaemia patients with myocardial siderosis
by: Pennell, D., et al.
Published: (2010) -
Efficacy of deferasirox in patients with thalassaemia major is not affected by a history of hepatitis B OR C
by: Cappellini, M.D., et al.
Published: (2010) -
Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
by: Cappellini, M.D., et al.
Published: (2010)